CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900., Gönen, Mithat, Sun Zhuoxin, Figueroa Maria E., Patel Jay P., Abdel-Wahab Omar, Racevskis Janis, Ketterling Rhett P., Fernandez Hugo, Rowe Jacob M., Tallman Martin S., et al. , Blood, 2012 Sep 13, Volume 120, Issue 11, p.2297-306, (2012)

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation., Figueroa, Maria E., Skrabanek Lucy, Li Yushan, Jiemjit Anchalee, Fandy Tamer E., Paietta Elisabeth, Fernandez Hugo, Tallman Martin S., Greally John M., Carraway Hetty, et al. , Blood, 2009 Oct 15, Volume 114, Issue 16, p.3448-58, (2009)

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905., Prebet, Thomas, Sun Zhuoxin, Figueroa Maria E., Ketterling Rhett, Melnick Ari, Greenberg Peter L., Herman James, Juckett Mark, Smith Mitchell R., Malick Lisa, et al. , J Clin Oncol, 2014 Apr 20, Volume 32, Issue 12, p.1242-8, (2014)